Satellos Bioscience Inc Com V.ICO

RE:RE:RE:RE:RE:Question to ALL

[allain250]

The above links show an incrediable array of world class talent all under one roof. And its very obvious that their interests are aligned with shareholders interests. Firstly they buy their own shares in Private Placements (financings) AND in the market. Secondly they do financings at market with no attached warrants. And thirdly the top five key employees took a 20% pay cut (since restored, but pay hasn’t been increased) when things went to hell in the markets. Very impressive and so damn rare to find insiders with so much “skin” in the game! Company management also has a very realistic end game plan. The objective of iCo over the next few years is to add substantial value to existing assets and subsequently monetize them for the benefit of shareholders. This could take the form of an acquisition of iCo (e.g. Aspreva Pharmaceuticals) or such other mechanism whereby the value can be transferred to shareholders. It is not the objective of the company to build a large permanent, integrated pharmaceutical company. I’m in complete agreement, build as much value into each product as is reasonable, then sell, let your shareholders reap the rewards and move on. Conclusion It’s been a very long time, if ever, since I’ve come across a stock with as much blue sky potential as iCo Therapeutics. Great management, obviously on side with shareholders, tight share structure, confirmation from others about the effectiveness of their products and a socially responsible investment that in my opinion makes one feel good about investing. That’s hard to beat. iCo’s share price is presently very cheap for a company in this sector. But with conference season starting and news from three drugs starting to flow soon I don’t expect the stock to stay long at present price levels.